DNA甲基化位点对肺腺癌预后的作用研究

doi:10.3969/j.issn.1000-8535.2022.03.026

广州医药 ›› 2022, Vol. 53 ›› Issue (3): 112-117.DOI: 10.3969/j.issn.1000-8535.2022.03.026

DNA甲基化位点对肺腺癌预后的作用研究

刘颖¹, 方子晗², 张雅琴², 王可^2,3

1 广州市第一人民医院(广州 510180)
2 湖北文理学院基础医学院预防医学教研室(襄阳441053)
3 湖北文理学院附属襄阳市中心医院,临床循证与转化医学中心(襄阳441053)

收稿日期:2021-10-08 出版日期:2022-05-20 发布日期:2022-07-01
通讯作者: 王可,E-mail: mqlhome76@163.com
基金资助:
湖北省教育厅科学技术研究计划青年人才项目(Q20212605);湖北省大学生创新训练项目(S2020105109031);湖北文理学院教师科研能力培育基金(2020kypyfy030)

Effect of DNA methylation sites on prognosis of lung adenocarcinoma

LIU Ying¹, FANG Zihan², ZHANG Yaqin², WANG Ke^2,3

1 Guangzhou First People's Hospital, Guangzhou 510180, China
2 Department of Preventive Medicine, Medical College, Hubei University of Arts and Sciences,Xiangyang 441053,China
3 Research Centre for Evidence-Based and Translational Medicine, Xiangyang Central Hospital, Affiliated hospital of Hubei University of Arts and Science, Xiangyang 441053, China

Received:2021-10-08 Online:2022-05-20 Published:2022-07-01

摘要/Abstract

摘要： 目的使用TCGA数据库,探索DNA甲基化位点对肺腺癌的预后影响。方法使用TCGA数据库,获取肺腺癌病人癌和癌旁组织甲基化表达数据、基因表达数据及临床数据;将人群分为探索组和验证组,使用LASSO在探索人群中筛选对肺腺癌预后有影响的甲基化位点;受试者工作特征曲线用于评估甲基化位点预测效果,并进一步在验证人群中验证。结果在TCGA数据库中筛选出158个癌和癌旁组织差异表达且与所在基因mRNA表达显著相关的甲基化位点,经LASSO回归分析,cg19378330与肺腺癌预后相关。甲基化位点水平高于中位数的患者,归入高风险组,甲基化位点水平低于中位数的为低风险组。结果发现与低风险组相比,高风险组的死亡风险比低风险组增加了38%(OR=1.38,95% CI=1.16～2.69)。在探索阶段人群中其曲线下面积为0.80(95% CI=0.73～0.88),灵敏度为86.2%。验证人群中也表现出类似结果。结论甲基化位点cg19378330与肺腺癌具有较显著的关联性,且可以对肺腺癌的风险进行有效的预测。

关键词: 肺腺癌, TCGA数据库, DNA甲基化, 预后

Abstract: Objective Using the TCGA database to explore the prognostic effects of DNA methylation sites on lung adenocarcinoma. Methods TCGA database was used to collecting DNA methylation data, gene expression data and clinical data of lung adenocarcinoma patients. The population were divided into the exploratory group and the validation group. The LASSO regression analysis was used to screen the methylation sites associated with the prognosis of lung adenocarcinoma in the exploratory group. Receiver operating characteristic curve was used to evaluate the prediction effect of the model, and further verified in the validation population. Results A total of 158 methylation sites with differential expression and significant correlation with the mRNA expression of the corresponding gene were screened from the TCGA database. With LASSO regression analysis, the DNA methylation sites associated with prognosis of lung adenocarcinoma were cg19378330. Those patients with levels above the median methylation site were assigned to the high-risk group, while those with levels below the median methylation site were assigned to the low-risk group. Patients' death risk in the high-risk group were 38% higher than those in the low-risk group (OR=1.38, 95%CI=1.16-2.69). The area under the curve was 0.80 (95%CI=0.73-0.88) and the sensitivity was 86.2% in the exploratory stage population.Similar results were seen in the validation population. Conclusions The DNA methylation site cg19378330 was significantly associated withthe prognosisof lung adenocarcinoma, and could effectively predict the risk of lung adenocarcinoma.

Key words: lung adenocarcinoma, TCGA database, DNA methylation, prognosis

刘颖, 方子晗, 张雅琴, 王可. DNA甲基化位点对肺腺癌预后的作用研究[J]. 广州医药, 2022, 53(3): 112-117.

LIU Ying. Effect of DNA methylation sites on prognosis of lung adenocarcinoma[J]. Guangzhou Medical Journal, 2022, 53(3): 112-117.

参考文献

[1] WADOWSKA K, BIL-LULA I, TREMBECKI Ł, et al. Genetic markers in lung cancer diagnosis: A review[J]. Int J MolSci, 2020,21(13):4569.
[2] MOLINA J R, YANG P, CASSIVI S D, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship[J]. Mayo ClinProc, 2008,83(5):584-594.
[3] XI K X, ZHANG X W, YU X Y, et al. The role of plasma miRNAs in the diagnosis of pulmonary nodules[J]. J Thorac Dis, 2018,10(7):4032-4041.
[4] YANG Z, LIU B, LIN T, et al. Multiomics analysis on DNA methylation and the expression of both messenger RNA and microRNA in lung adenocarcinoma[J]. J Cell Physiol, 2019,234(5):7579-7586.
[5] SADIKOVIC B, AL-ROMAIH K, SQUIRE J A, et al. Cause and consequences of genetic and epigenetic alterations in human cancer[J]. Curr Genomics, 2008,9(6):394-408.
[6] JONES P A. DNA methylation errors and cancer[J]. Cancer Res, 1996,56(11):2463-2467.
[7] Li R, Yang Y E, Yin Y H, et al. Methylation and transcriptome analysis reveal lung adenocarcinoma-specific diagnostic biomarkers[J]. J Transl Med, 2019,17(1):324.
[8] SAITO K, KAWAKAMI K, MATSUMOTO I, et al. Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer[J]. Clin Cancer Res, 2010,16(8):2418-2426.
[9] WEINSTEIN J N, COLLISSON E A, MILLS G B, et al. The Cancer Genome Atlas Pan-Cancer analysis project[J]. Nat Genet, 2013,45(10):1113-1120.
[10] ROST D, MAHNER S, SUGIYAMA Y, et al. Expression and localization of the multidrug resistance-associated protein 3 in rat small and large intestine[J]. Am J PhysiolGastrointest Liver Physiol, 2002,282(4):G720-G726.
[11] ITO K, OLESCHUK C J, WESTLAKE C, et al. Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity[J]. J BiolChem, 2001,276(41):38108-38114.
[12] SHARIFI M J, BAHOUSH G, ZAKER F, et al. Association of -24CT, 1249GA, and 3972CT ABCC2 gene polymorphisms with methotrexate serum levels and toxic side effects in children with acute lymphoblastic leukemia[J]. PediatrHematolOncol, 2014,31(2):169-177.
[13] LIU Y, YIN Y, SHENG Q, et al. Association of ABCC2-24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia[J]. PLoS One, 2014,9(1):e82681.
[14] HAN Z G, TAO J, YU T T, et al. Effect of GSTP1 and ABCC2 Polymorphisms on treatment response in patients with advanced non-small cell lung cancer undergoing platinum-based chemotherapy: A study in a Chinese Uygur population[J]. Med SciMonit, 2017,23:1999-2006.
[15] CAMPA D, MÜLLER P, EDLER L, et al. A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis[J]. Int J Cancer, 2012,131(12):2920-2928.
[16] HAN B, GAO G, WU W, et al. Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients[J]. Lung Cancer, 2011,72(2):238-243.
[17] SUZUKI H, SUGIYAMA Y. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition[J]. Adv Drug Deliv Rev, 2002,54(10):1311-1331.
[18] CUFFE S, AZAD A K, QIU X, et al. ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients[J]. Cancer Epidemiol, 2016(41):50-56.

DNA甲基化位点对肺腺癌预后的作用研究

Effect of DNA methylation sites on prognosis of lung adenocarcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈婷女, 梁慕琼, 梁亮. 儿童重症肺炎支气管肺泡灌洗液病原学及疾病预后分析[J]. 广州医药, 2022, 53(3): 53-56.
[2]	王俊, 闫娅, 李永红, 李佳. 分析CT肺动脉栓塞指数与急性肺栓塞患者右心功能及预后的相关性[J]. 广州医药, 2022, 53(2): 120-123.
[3]	吴天源, 罗义, 吕磊, 谭文亮, 孙少喜. CYP2C19基因多态性与急性心肌梗死患者炎症指标、临床预后的相关性[J]. 广州医药, 2022, 53(1): 1-5.
[4]	陶豫东. 益生菌结合肠内营养干预纠正缺血性急性脑卒中患者肠道菌落紊乱的作用及对其预后的影响[J]. 广州医药, 2022, 53(1): 109-113.
[5]	肖驰, 周雪, 徐丹, 杨美英, 费晶, 巩平. SNCG在卵巢癌中的表达及其临床意义[J]. 广州医药, 2021, 52(5): 1-7.
[6]	古嘉基, 连泳欣, 丘福满. m6A甲基化基因风险评估模型在卵巢癌预后的临床意义[J]. 广州医药, 2021, 52(3): 1-8.
[7]	谢艳林, 董燕, 柳建华. 经胸超声心动图在Stanford A型主动脉夹层的诊断及预后评估中的价值[J]. 广州医药, 2021, 52(3): 36-40.
[8]	罗水妹, 黄颂平, 许白兰, 沈冰寒. 肺癌并发肺栓塞的危险因素及预后分析[J]. 广州医药, 2021, 52(2): 40-45.
[9]	钟玲. Napsin A、TTF-1及CK7在恶性胸水中对肺腺癌的诊断价值[J]. 广州医药, 2021, 52(2): 66-69.
[10]	岑昕贝, 凌济忠, 万跃平, 万颂, 华伟, 江敏耀, 习明. NR3C1表达与前列腺癌生化复发的相关性研究[J]. 广州医药, 2020, 51(4): 22-27.
[11]	刘霞, 方喜生, 翁成荫, 伍勇, 毛海波, 李宝秀, 王丽娜, 刘国龙. 原发性肝癌患者循环肿瘤细胞检测及其与术后复发转移的关系[J]. 广州医药, 2020, 51(2): 36-39.
[12]	梁春艳. 二氢丹参酮I在胃癌AGS细胞中作用机制的生物信息学分析[J]. 广州医药, 2020, 51(2): 85-93.
[13]	李赟, 李勇, 巩平, 李小英, 李娜. 中性粒细胞与淋巴细胞比值在晚期不可切除结直肠癌患者化疗疗效及预后的意义[J]. 广州医药, 2020, 51(1): 59-65.
[14]	林颖欣, 庞丹梅, 胡倩, 段海波, 李财枝. D-二聚体在女性恶性肿瘤病情监测中的应用价值[J]. 广州医药, 2019, 50(2): 28-33.
[15]	张艳芳, 周洁, 杨宜帆, 殷思诺, 王丽. 372例老年冠脉支架植入患者临床特征及预后分析[J]. 广州医药, 2019, 50(2): 85-87.